ALPS Medical Breakthroughs ETF SBIO

Morningstar Medalist Rating

Morningstar’s Analysis SBIO

Will SBIO outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

ALPS Medical Breakthroughs ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings SBIO

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings33.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

CG Oncology Inc

5.099M
Healthcare

Oruka Therapeutics Inc

4.458M
Healthcare

Veradermics Inc

3.637M
Healthcare

Dianthus Therapeutics Inc

3.406M
Healthcare

Edgewise Therapeutics Inc

3.216M
Healthcare

Travere Therapeutics Inc Ordinary Shares

3.176M
Healthcare

Definium Therapeutics Inc Ordinary Shares

2.745M
Healthcare

Xenon Pharmaceuticals Inc

2.585M
Healthcare

Relay Therapeutics Inc Ordinary Shares

2.575M
Healthcare

Amylyx Pharmaceuticals Inc

2.374M
Healthcare

Sponsor Center